Qrons Inc., a biotechnology company, develops biotech products, treatments, and technologies to combat neuronal and infectious diseases. Its product candidates include QS100, an injury specific, 3D printable, implantable mesenchymal stem cells (MSCs)-synthetic hydrogel to treat penetrating brain injuries; and QS200, an injectable MSCs-synthetic hydrogel for the treatment of concussions and other diffused axonal injuries. The company was formerly known as BioLabMart Inc. and changed its name to Qrons Inc. in August 2017. Qrons Inc. was incorporated in 2016 and is based in Long Island City, New York.